These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16679001)

  • 1. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood.
    Saeedi H; Remington G; Christensen BK
    Schizophr Res; 2006 Jul; 85(1-3):222-31. PubMed ID: 16679001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial.
    Mas S; Gassó P; Fernández de Bobadilla R; Arnaiz JA; Bernardo M; Lafuente A
    Hum Psychopharmacol; 2013 Nov; 28(6):586-93. PubMed ID: 24519692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
    Goldberg TE; Bigelow LB; Weinberger DR; Daniel DG; Kleinman JE
    Am J Psychiatry; 1991 Jan; 148(1):78-84. PubMed ID: 1984711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
    Bech P; Tanghøj P; Andreasson K; Overø KF
    Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group.
    Awad AG; Lapierre YD; Angus C; Rylander A
    J Psychiatry Neurosci; 1997 Jul; 22(4):244-8. PubMed ID: 9262046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
    Rémillard S; Pourcher E; Cohen H
    Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.